查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198087

PGT（植入前基因检测）市场——增长、趋势、COVID-19 影响和预测 (2023-2028)

Preimplantation Genetic Testing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

PGT（植入前基因检测）市场预计在预测期内以 10.5% 的复合年增长率增长。

在 COVID-19 期间，植入前基因检测的采用正在增加，预计这将推动市场增长。 在 2021 年 10 月发表的一篇 NCBI 文章中，PGT（植入前基因检测）和胚胎学家的专业知识提供安全和辅助生殖技术过程有 COVID-19 感染的既往史，并指出对患者没有不良影响。 然而，NCBI 于 2022 年 9 月发表的另一篇论文发现，怀孕期□□间感染 COVID-19 的妇女可能会增加产科和新生儿并发症的风险。 此类感染者出现产前并发症的风险将在大流行期间增加对 PGT（植入前基因检测）的需求。 因此，预计 COVID-19 大流行将促进市场增长，并在研究的预测期内保持同样的增长势头。

市场增长的主要驱动因素是分娩并发症导致的新生儿死亡率高，以及父母对诊断技术进步的认识不断提高。 近年来，爱德华兹综合征等先天性遗传病和肺炎、哮喘等儿童常见呼吸系统疾病的患病率有所增加。 根据 2021 年 8 月发表的 NCBI 文章，南非先天性异常的机构出生患病率为每 1,000 名活产婴儿 15.57 例。 根据 2022 年 9 月发布的另一份 NCBI 数据，英国爱德华兹综合征的出生患病率从 3600 分之一到 10,000 分之一不等。 据观察，这些异常几乎只发生在患有遗传性疾病的夫妇中，而且主要发生在发达国家。 因此，对早期诊断的需求增加和政府为控制医疗负担所做的努力预计将推动 PGT（植入前基因检测）市场。

此外，各种市场参与者发布的产品数量增加预计将在预测期内推动市场增长。 例如，Eurofins Genoma 于 2022 年 9 月推出了无创 niPGT-A。 这是一种无胚胎活检的植入前遗传非整倍体筛查试验。 为 IVF 设施提供高度准确的替代传统 PGT-A 测试的方法。

因此，预计在预测期内，先天性遗传病患病率增加和产品发布增加等因素将促进市场增长。 然而，研究人群规模小、伦理问题、昂贵的测试程序、不利的监管框架、开发阶段的挑战等可能会抑制预测期内的市场增长。

植入前基因检测 (PGT) 市场趋势

在PGT（植入前基因检测）市场中，体外受精预后预计在预测期内将占据较大的市场份额

体外受精 (IVF) 是一种辅助生殖技术，用于治疗某些遗传和不孕不育问题。 IVF预后是通过PGT（Preimplantation Genetic Testing）方法检查胚胎健康状况的必要步骤。 因此，PGT（植入前基因检测）在体外受精的预后中起着重要作用，从而有助于研究部分的生长。 体外受精预测领域有望占据PGT（胚胎植入前基因检测）市场的很大份额。 这主要是由于对 PGT（植入前基因检测）程序的需求增加导致大量体外受精程序。

例如，根据 2022 年 5 月更新的 MayoClinic 文章，全球有 10-12% 的夫妇难以怀孕，预计这一比例在未来几年内会逐渐增加。 IVF 分别占美国和欧洲所有活产的 1.6% 和 4.5%。 文章还指出，约有25%至35%的不孕妇女患有腹膜下疾病。 盆腔炎 (PID) 是不孕症最常见的原因，而男性精液质量差是导致 20% 夫妇不孕的唯一原因。 因此，难孕人群的沉重负担和生育率下降促成了这一细分市场的增长。

此外，在预测期内，各种市场参与者推出的产品数量不断增加，预计将推动所研究细分市场的增长。 例如，2022年7月，GenEmbryonics推出了商业化的全基因组测序测试，有效筛查试管婴儿胚胎中的所有遗传病。 这项综合测试揭示了胚胎的基因组序列，从而可以识别和筛选致病突变。

因此，不孕症增加、对体外受精的偏好增加以及体外受精预后产品发布的增加等因素预计将在预测期内推动研究细分市场的增长。

预计在预测期内北美将占 PGT（胚胎植入前基因检测）市场的很大份额

预计北美将主导 PGT（植入前基因检测）市场。 这种优势归因于导致各种遗传性疾病的染色体异常病例的增加。 此外，该地区消费者意识的提高和重要市场参与者的存在也是该地区市场增长的推动因素。

根据美国疾病控制与预防中心 (CDC) 2021 年 4 月的一份报告，美国每年约有 6,000 名婴儿患有唐氏综合症。 同样，加拿大不列颠哥伦比亚省在 2021 年 2 月发表的一篇文章中指出，在加拿大出生的每 750 个婴儿中就有一个患有唐氏综合症。 此外，2021 年 11 月发表在 Facets Journal 上的数据表明，这种罕见疾病影响了大约二分之一的加拿大人，其中大多数有潜在的遗传原因。 因此，对早期诊断以识别胚胎遗传异常的需求增加，推动了该地区的市场。

市场参与者的活动增加，例如北美的合作伙伴关係、合併和产品开发联合研究，预计也将有助于市场的增长。 例如，2022 年 10 月，Ovation Fertility 与 Genomic Prediction 合作，授权 LifeView PGT 基因检测平台。 Lifeview PGT 提供当今最全面的植入前胚胎基因检测。

因此，遗传疾病的高负担和市场参与者的活跃度增加，加上北美国家对 PGT（植入前基因检测）意识的增强，将引领该地区的市场在预测期内增长。预计促进增长。

植入前基因检测 (PGT) 市场竞争对手分析

PGT（植入前基因检测）市场竞争适中，由几家主要参与者组成。 主导市场的几个主要参与者采取了各种策略，例如专注于研发和推出新产品。 目前主导市场的主要公司包括 The Cooper Companies Inc.、Illumina Inc.、Thermo Fisher Scientific Inc.、PerkinElmer Inc.、Bioarray SL。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 帕陶氏综合症、爱德华氏综合症和唐氏综合症等遗传性疾病的负担越来越重
    • 政府在提高先进诊断设备开发意识和研发活动方面所做的努力
  • 市场製约因素
    • 研究对像数量少且存在伦理问题
    • 昂贵的检查程序
    • 不利的监管框架和发展过程中的挑战
  • 波特的五力分析
    • 供应商的议价能力
    • 买方/消费者议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按测试类型
    • 植入前遗传学诊断 (PGD)
    • 植入前基因筛查 (PGS)
  • 按产品/服务
    • 检验设备
    • 试剂和耗材
    • 软件服务
  • 通过申请
    • HLA 分型
    • 体外受精的预后测定
    • 非整倍体筛查
    • 其他应用
  • 最终用户
    • 医院和诊断实验室
    • 产科和不孕不育中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • The Cooper Companies Inc.
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • Quest Diagnostics Inc.
    • PerkinElmer Inc.
    • Invitae Corp.
    • Natera Inc.
    • Igenomix Sl
    • Bioarray SL
    • Genea Ltd

第七章市场机会与未来趋势

简介目录
Product Code: 68439

The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.

During COVID-19, there was an increasing adoption of the preimplantation of genetic testing, which is expected to drive the market's growth. The NCBI article published in October 2021 mentioned preimplantation genetic testing and embryologist specialization provided safety and assisted reproduction process have not negatively impacted patients with a previous record of COVID-19 infection. However, according to another NCBI article published in September 2022, women with COVID-19 during Pregnancy might have a higher risk of obstetrical and neonatal complications. Such risk of pre-natal complications in the infected patients boosted the demand for preimplantation genetic testing during the pandemic. Thus, the COVID-19 pandemic has increased the market's growth, which is expected to follow the same traction during the forecast period of the study.

The primary factor attributing to the market's growth is a rising awareness among parents regarding advancements in diagnostics, with a massive volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome and common pediatric respiratory disorders such as pneumonia and asthma has been observed in recent years. As per the NCBI article published in August 2021, the in-facility birth prevalence rate for congenital abnormalities in South Africa was 15.57 per 1,000 live births. Another NCBI published in September 2022 states that the live birth prevalence with Edwards syndrome in the UK ranges from 1 in 3600 to 1 in 10,000. These abnormalities occur almost exclusively in couples with hereditary disorders, which were observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and government initiatives to control the healthcare burden will likely drive the preimplantation genetic testing market.

Additionally, the increasing product launches by various market players are expected to boost market growth over the forecast period. For instance, Eurofins Genoma launched the niPGT-A, a non-non-invasive, in September 2022. It is an embryo biopsy-free, preimplantation genetic aneuploidy screening test. It provides IVF centers with access to a highly accurate alternative to traditional PGT-A testing.

Thus, the factors such as the growing prevalence of congenital genetic diseases and increasing product launches are expected to contribute to the market's growth over the forecast period. However, the small size of the study population and ethical concerns, costly testing procedures, and unfavorable regulatory framework and challenges during the development stage may restrain the market's growth over the forecast period.

Preimplantation Genetic Testing Market Trends

IVF Prognosis is Expected to Hold a Significant Market Share in the Preimplantation Genetic Testing Market Over the Forecast Period

Invitro fertilization(IVF) is a method of assisted reproduction and treatment for specific genetic and fertility issues. The prognosis for IVF is a necessary procedure to inspect the medical condition of the embryos by preimplantation genetic testing methods. Thus, preimplantation genetic testing plays a crucial role in the IVF prognosis, thereby contributing to the growth of the studied segment. The IVF prognosis segment is expected to account for a significant share of the preimplantation genetic testing market. It is mainly due to the high number of invitro fertilization procedures owing to the increased demand for preimplantation genetic testing procedures.

For instance, according to the MayoClinic article updated in May 2022, globally, 10-12% of couples have difficulty conceiving, which is expected to increase gradually in the coming years. IVF accounts for 1.6% and 4.5% of all US and Europe live births, respectively. Also, the same article quoted that approximately 25% to 35% of infertile women have a subperitoneal disease. Pelvic inflammatory disease (PID) is the most common cause of infertility, and poor semen quality in men is the sole cause of infertility in 20% of couples. Such a high burden of people having difficulty conceiving and a decrease in fertility rates contributes to the segment's growth.

Additionally, the rising product launches by various market players are expected to drive the growth of the studied segment over the forecast period. For instance, in July 2022, GenEmbryonics launched the commercial whole genome sequencing test for effectively screening all genetic diseases in IVF embryos. This comprehensive testing clarifies the embryo's genome sequence, allowing disease-causing mutations to be identified and screened.

Thus, factors such as rising infertility, increasing preference for IVF procedures, and growing product launches for IVF prognosis are expected to drive the growth of the studied segment over the forecast period.

North America is Expected to Hold a Significant Share in the Preimplantation Genetic Testing Market Over the Forecast Period

North America is expected to dominate the preimplantation genetic testing market. The dominance is due to a growing volume of cases of chromosome abnormality leading to various genetic disorders. Additionally, the increasing consumer awareness and the presence of significant market players in this region are also driving factors for the growth of the market in this region.

According to the Centers for Disease Control and Prevention (CDC) report in April 2021, about 6,000 babies born in the US have down syndrome every year. Similarly, the Province of British Columbia, Canada, an article published in February 2021, mentioned that in Canada, one in every 750 live babies born has Down syndrome. Additionally, the data published in Facets Journal in November 2021 noted that rare diseases affect approximately 1 in 12 Canadians, and most have underlying genetic causes. It, in turn, resulted in high demand for earlier diagnoses to identify the genetic defects in embryos, thus driving the market in the region.

The increasing market player's activities, such as partnerships, mergers, and collaborations in North America to develop products, are also expected to contribute to the market's growth. For instance, in October 2022, Ovation Fertility partnered with Genomic Prediction to license the LifeView PGT platform for genetic testing. This Lifeview PGT provides the most comprehensive currently available genetic test of the preimplantation embryo.

Thus, the high burden of genetic diseases and increasing market players' activities, coupled with the rising awareness regarding preimplantation genetic testing in North American countries, is expected to drive the market's growth in this region over the forecast period.

Preimplantation Genetic Testing Market Competitor Analysis

The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and launching new products. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome
    • 4.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices
  • 4.3 Market Restraints
    • 4.3.1 Small Size of Study Population and Ethical Concerns
    • 4.3.2 Highly Expensive Testing Procedures
    • 4.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Test Type
    • 5.1.1 Preimplantation Genetic Diagnosis (PGD)
    • 5.1.2 Preimplantation Genetic Screening (PGS)
  • 5.2 By Product and Service
    • 5.2.1 Instruments
    • 5.2.2 Reagents and Consumables
    • 5.2.3 Software and Services
  • 5.3 By Application
    • 5.3.1 HLA Typing
    • 5.3.2 IVF Prognosis
    • 5.3.3 Aneuploidy Screening
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals and Diagnostic Labs
    • 5.4.2 Maternity Centers and Fertility Clinics
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 The Cooper Companies Inc.
    • 6.1.2 Illumina Inc.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Quest Diagnostics Inc.
    • 6.1.5 PerkinElmer Inc.
    • 6.1.6 Invitae Corp.
    • 6.1.7 Natera Inc.
    • 6.1.8 Igenomix Sl
    • 6.1.9 Bioarray SL
    • 6.1.10 Genea Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS